Oncolix, Inc.
Records under this name other than patents Oncolix, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,550,426 | Acetylated therapeutic procytotoxins Formerly held Term ended Term ended May 16, 2026 · From the USPTO record | Term ended | Term ended May 16, 2026 | From the USPTO record |
| US 7,339,027 | Human Prolactin Antagonist-Angiogensis Inhibitor Fusion Proteins Term ended Term ended Feb 1, 2025 · High confidence | Term ended | Term ended Feb 1, 2025 | High confidence |
| US 7,456,146 | Lytic peptide prodrugs Formerly held Term ended Term ended Mar 11, 2024 · From the USPTO record | Term ended | Term ended Mar 11, 2024 | From the USPTO record |
| US 7,201,905 | Bi-functional cancer treatment agents Term ended Term ended Sep 14, 2023 · From the USPTO record | Term ended | Term ended Sep 14, 2023 | From the USPTO record |
| US 7,425,535 | Therapeutic pore-forming peptides Formerly held Term ended Term ended Aug 4, 2022 · From the USPTO record | Term ended | Term ended Aug 4, 2022 | From the USPTO record |
| US 8,754,031 | Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway Lapsed on the fee record Ended Jun 17, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jun 17, 2022 | From the USPTO record |
| US 8,754,035 | Compositions and methods for visualizing and eliminating cancer stem cells Lapsed on the fee record Ended Jun 17, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jun 17, 2022 | From the USPTO record |
| US 8,648,046 | Compositions and methods for visualizing and eliminating cancer stem cells Lapsed on the fee record Ended Feb 11, 2022 · From the USPTO record | Lapsed on the fee record | Ended Feb 11, 2022 | From the USPTO record |
| US 7,632,809 | Multimeric ligands with enhanced stability Lapsed on the fee record Ended Dec 15, 2021 · From the USPTO record | Lapsed on the fee record | Ended Dec 15, 2021 | From the USPTO record |
| US 6,849,451 | Hybrid cells Formerly held Term ended Term ended Jan 9, 2021 · From the USPTO record | Term ended | Term ended Jan 9, 2021 | From the USPTO record |